• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Cardinal Health Inc.

    11/18/24 6:30:31 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email
    8-K
    CARDINAL HEALTH INC false 0000721371 0000721371 2024-11-13 2024-11-13

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 13, 2024

     

     

    Cardinal Health, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Ohio   1-11373   31-0958666

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    7000 Cardinal Place, Dublin, Ohio 43017

    (Address of Principal Executive Offices) (Zip Code)

    (614) 757-5000

    (Registrant’s telephone number, including area code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common shares (without par value)   CAH   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    ITEM 8.01

    Other Events.

    On November 13, 2024, Cardinal Health, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein, for the sale by the Company of $500,000,000 aggregate principal amount of its 4.700% Notes due 2026, $750,000,000 aggregate principal amount of its 5.000% Notes due 2029, $1,000,000,000 aggregate principal amount of its 5.350% Notes due 2034 and $650,000,000 aggregate principal amount of its 5.750% Notes due 2054. The offering was made pursuant to the Company’s effective registration statement on Form S-3 (Registration Statement No. 333-268237) previously filed with the Securities and Exchange Commission.

    A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing summary of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to full text of the Underwriting Agreement.

     

    ITEM 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    Number.

      

    Description

    1.1    Underwriting Agreement, dated as of November 13, 2024, among Cardinal Health, Inc. and BofA Securities, Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        CARDINAL HEALTH, INC.
    Date: November 18, 2024     By:  

    /s/ Aaron E. Alt

        Name:   Aaron E. Alt
        Title:   Chief Financial Officer
    Get the next $CAH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CAH

    DatePrice TargetRatingAnalyst
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    12/4/2024$139.00Outperform
    Mizuho
    2/26/2024$125.00Outperform
    Leerink Partners
    More analyst ratings

    $CAH
    SEC Filings

    See more
    • SEC Form 11-K filed by Cardinal Health Inc.

      11-K - CARDINAL HEALTH INC (0000721371) (Filer)

      6/20/25 8:32:15 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • SEC Form 11-K filed by Cardinal Health Inc.

      11-K - CARDINAL HEALTH INC (0000721371) (Filer)

      6/20/25 8:31:24 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CARDINAL HEALTH INC (0000721371) (Filer)

      6/12/25 6:47:01 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2025 on August 12

      DUBLIN, Ohio, July 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2025 on August 12, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months. About Cardinal He

      7/15/25 6:45:00 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health announces One Voice Initiative to support independent pharmacy advocacy

      DUBLIN, Ohio, July 11, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced the launch of the Cardinal Health™ One Voice Initiative for pharmacy advocacy, which provides direct financial assistance to state pharmacy associations for the purpose of supporting independent pharmacists' advocacy efforts.   This investment furthers Cardinal Health's longstanding advocacy around the future of independent pharmacies and ongoing partnerships with industry organizations to support pharmacists' efforts to build relationships with elected officials at all levels of government.

      7/11/25 8:30:00 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • After Major Oncology Conference, All Eyes Turn to Industry Innovation

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

      6/12/25 9:00:00 AM ET
      $CAH
      $CTOR
      $CTXR
      $ONCY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal/Compliance Officer Mayer Jessica L covered exercise/tax liability with 5,176 shares, decreasing direct ownership by 9% to 55,110 units (SEC Form 4)

      4 - CARDINAL HEALTH INC (0000721371) (Issuer)

      6/30/25 4:18:28 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • CEO, GMPD Segment Mason Stephen M covered exercise/tax liability with 5,694 shares, decreasing direct ownership by 14% to 34,977 units (SEC Form 4)

      4 - CARDINAL HEALTH INC (0000721371) (Issuer)

      6/30/25 4:17:48 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Hollar Jason M. covered exercise/tax liability with 5,821 shares, decreasing direct ownership by 3% to 191,815 units (SEC Form 4)

      4 - CARDINAL HEALTH INC (0000721371) (Issuer)

      6/30/25 4:16:56 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cardinal Health upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

      6/3/25 7:24:57 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health upgraded by Jefferies with a new price target

      Jefferies upgraded Cardinal Health from Hold to Buy and set a new price target of $150.00 from $140.00 previously

      2/5/25 7:09:45 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health upgraded by TD Cowen with a new price target

      TD Cowen upgraded Cardinal Health from Hold to Buy and set a new price target of $144.00 from $130.00 previously

      1/8/25 7:36:58 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    Financials

    Live finance-specific insights

    See more
    • Cardinal Health Board of Directors Approves Quarterly Dividend

      DUBLIN, Ohio, May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2025, to shareholders of record at the close of business on July 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an op

      5/5/25 5:30:00 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

      Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expirationGAAP1 operating earnings were $730 million; GAAP diluted EPS was $2.10Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35Fiscal year 2025 non-GAAP EPS guidance2 raised and narrowed to $8.05 to $8.15, from $7.85 to $8.00GI Alliance announces expansion into urology specialty therapeutic areaDUBLIN, Ohio, May 1, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2025 revenues of $54.9 billion,

      5/1/25 6:45:00 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health Board of Directors Approves Quarterly Dividend

      DUBLIN, Ohio, Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2025, to shareholders of record at the close of business on April 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nucle

      2/3/25 5:15:00 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    Leadership Updates

    Live Leadership Updates

    See more
    • After Major Oncology Conference, All Eyes Turn to Industry Innovation

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

      6/12/25 9:00:00 AM ET
      $CAH
      $CTOR
      $CTXR
      $ONCY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Carlisle Companies Announces Leadership Appointments

      Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

      5/16/25 4:05:00 PM ET
      $CAH
      $CSL
      $SUM
      $WU
      Other Pharmaceuticals
      Health Care
      Specialty Chemicals
      Industrials
    • Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

      DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

      3/10/25 6:45:00 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

      SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

      2/13/24 5:01:02 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

      SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

      1/30/24 1:39:03 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

      SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

      2/14/23 12:37:58 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care